Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway

References

• D MILLERK, Nogueira L, B MARIOTTOA, et al. Cancer treatment and survivorship statistics, 2019 [J]. CA Cancer J Clin. 2019;69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Richters A, H ABENKK, Kiemeney L. The global burden of urinary bladder cancer: an update [J]. World J Urol. 2020;38(8):1895–1904.
   PubMed Web of Science ®Google Scholar
• Z LIH, S ZHENGR, B DUL, et al. Bladder cancer incidence, mortality and temporal trends in China] [J. Zhonghua Zhong Liu Za Zhi. 2021;43(3):293–298.
   PubMedGoogle Scholar
• Grayson M. Bladder cancer [J]. Nature. 2017;551(7679):S33.
   PubMed Web of Science ®Google Scholar
• L SMITHZ, J GUZZOT. Urinary markers for bladder cancer [J]. F1000Prime Rep. 2013;5(21). DOI:10.12703/P5-21
   Google Scholar
• Palou J, Wood D, H BOCHNERB, et al. ICUD-EAU international consultation on bladder cancer 2012: urothelial carcinoma of the prostate [J]. Eur Urol. 2013;63(1):81–87.
   PubMed Web of Science ®Google Scholar
• Burger M, W CATTOJ, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer [J]. Eur Urol. 2013;63(2):234–241.
   PubMed Web of Science ®Google Scholar
• H AL-ZALABANIA, F STEWARTK, Wesselius A, et al. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses [J]. Eur J Epidemiol. 2016;31(9):811–851.
   PubMed Web of Science ®Google Scholar
• Piyathilake C. Dietary factors associated with bladder cancer [J]. Investig Clin Urol. 2016;57(Suppl 1):S14-25.
   Web of Science ®Google Scholar
• Oberoi S, Barchowsky A, WU F. The global burden of disease for skin, lung, and bladder cancer caused by arsenic in food [J]. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1187–1194.
   PubMed Web of Science ®Google Scholar
• B APOLOA, J VOGELZANGN, Theodorescu D. New and promising strategies in the management of bladder cancer [J]. Am Soc Clin Oncol Educ Book. 2015;105–112. DOI:10.14694/EdBook_AM.2015.35.105
   PubMedGoogle Scholar
• J DCOSTAJ, C GOLDSMITHJ, S WILSONJ, et al. A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer [J]. Bladder Cancer. 2016;2(3):301–317.
   PubMedGoogle Scholar
• Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes [J]. Eur Urol. 2016;69(2):300–310.
   PubMed Web of Science ®Google Scholar
• D THOMPSONP, SAKWE A, Koumangoye R, et al. Alpha-2 heremans Schmid glycoprotein (AHSG) modulates signaling pathways in head and neck squamous cell carcinoma cell line SQ20B [J]. Exp Cell Res. 2014;321(2):123–132.
   PubMed Web of Science ®Google Scholar
• M BROWNW, R SAUNDERSN, Mollgard K, et al. Fetuin–an old friend revisited [J]. Bioessays. 1992;14(11):749–755.
   PubMed Web of Science ®Google Scholar
• MORI K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein [J]. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(2):124–146.
   PubMedGoogle Scholar
• Denecke B, Graber S, SCHAFER C, et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A [J]. Biochem J. 2003;376(Pt 1):135–145.
   PubMedGoogle Scholar
• J CINTRONV, S KOM, D CHIK, et al. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha 2-HS glycoprotein [J]. Int J Exp Diabetes Res. 2001;1(4):249–263.
   PubMedGoogle Scholar
• T MATHEWSS, P SINGHG, Ranalletta M, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene [J]. Diabetes. 2002;51(8):2450–2458.
   PubMed Web of Science ®Google Scholar
• Miura Y, Iwazu Y, Shiizaki K, et al. Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease [J]. Sci Rep. 2018;8(1):1256.
   PubMedGoogle Scholar
• SCHAFER C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification [J]. J Clin Invest. 2003;112(3):357–366.
   PubMed Web of Science ®Google Scholar
• Guillory B, M SAKWEA, Saria M, et al. Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer [J]. Am J Pathol. 2010;177(5):2635–2644.
   PubMed Web of Science ®Google Scholar
• N KUNDRANDAM, Henderson M, J CARTERK, et al. The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms [J]. Cancer Res. 2005;65(2):499–506.
   PubMed Web of Science ®Google Scholar
• J SWALLOWC, A PARTRIDGEE, C MACMILLANJ, et al. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression [J]. Cancer Res. 2004;64(18):6402–6409.
   PubMed Web of Science ®Google Scholar
• DING D, CHEN M, Xiao X, et al. Novel serum peptide model revealed by MALDI-TOF-MS and its diagnostic value in early bladder cancer [J]. Int J Biol Markers. 2020;35(3):59–66.
   PubMed Web of Science ®Google Scholar
• Tong H, H YIN, A HOSSAINM, et al. Starvation-induced autophagy promotes the invasion and migration of human bladder cancer cells via TGF-beta1/Smad3-mediated epithelial-mesenchymal transition activation [J]. J Cell Biochem. 2019;120(4):5118–5127.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, WANG X, et al. The consensus molecular subtypes of colorectal cancer [J]. Nat Med. 2015;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• F XIE, LING L, VAN DAMH, et al. TGF-beta signaling in cancer metastasis [J]. Acta Biochim Biophys Sin (Shanghai). 2018;50(1):121–132.
   PubMed Web of Science ®Google Scholar
• WU S, XU R, X ZHU, et al. The long noncoding RNA LINC01140/miR-140-5p/FGF9 axis modulates bladder cancer cell aggressiveness and macrophage M2 polarization. Aging. 2020;12(24):25845–25864. J]. Aging (Albany NY).
   PubMedGoogle Scholar
• L CAOH, J LIUZ, L HUANGP, et al. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206 [J]. Eur Rev Med Pharmacol Sci. 2019;23(3):1012–1021.
   PubMed Web of Science ®Google Scholar
• ZHANG C, WANG W, J LIN, et al. lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion [J]. Int Braz J Urol. 2019;45(3):549–559.
   PubMed Web of Science ®Google Scholar
• J HAN, Z WANGJ, Yang X, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner [J]. Mol Cancer. 2019;18(1):110.
   PubMedGoogle Scholar
• W LUO, WANG J, XU W, et al. LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer [J]. Cell Death Dis. 2021;12(11):1043.
   PubMed Web of Science ®Google Scholar
• H HAO, CHEN H, L XIE, et al. YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition [J]. Ann Med. 2021;53(1):1170–1178.
   PubMed Web of Science ®Google Scholar
• M LIU, ZHANG X, CHEN H, et al. Serum sPD-L1, upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients [J]. Scand J Immunol. 2017;85(1):66–72.
   PubMed Web of Science ®Google Scholar
• P PATELS, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy [J]. Mol Cancer Ther. 2015;14(4):847–856.
   PubMed Web of Science ®Google Scholar
• Y ZHANGW, R WANGH, H HU, et al. Clinical features and diagnosis of encrusted bladder cancer] [J. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41(3):430–434.
   PubMedGoogle Scholar
• G HAN, YE M, Zhou H, et al. Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography [J]. Proteomics. 2008;8(7):1346–1361.
   PubMed Web of Science ®Google Scholar
• Ochieng J, Nangami G, SAKWE A, et al. Impact of fetuin-A (AHSG) on tumor progression and type 2 diabetes [J]. Int J Mol Sci. 2018;19(8):2211.
   PubMed Web of Science ®Google Scholar
• F SHI, WU H, QU K, et al. Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer [J]. Clin Proteomics. 2018;15(18). DOI:10.1186/s12014-018-9194-0.
   Google Scholar
• Y KWAKJ, Z MAT, J YOOM, et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia [J]. Exp Hematol. 2004;32(9):836–842.
   PubMed Web of Science ®Google Scholar
• Danda R, Ganapathy K, Sathe G, et al. Proteomic profiling of retinoblastoma by high resolution mass spectrometry [J]. Clin Proteomics. 2016;13(29). DOI:10.1186/s12014-016-9128-7.
   PubMedGoogle Scholar
• Massague J. TGFbeta signalling in context [J]. Nat Rev Mol Cell Biol. 2012;13(10):616–630.
   PubMed Web of Science ®Google Scholar
• Syed V. TGF-beta Signaling in Cancer [J]. J Cell Biochem. 2016;117(6):1279–1287.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, TIJERAS-RABALLAND A, Cohen R, et al. Targeting the TGFbeta pathway for cancer therapy [J]. Pharmacol Ther. 2015;147:22–31.doi:10.1016/j.pharmthera.2014.11.001.
   PubMed Web of Science ®Google Scholar
• R KONETYB. Molecular markers in bladder cancer: a critical appraisal [J]. Urol Oncol. 2006;24(4):326–337.
   PubMed Web of Science ®Google Scholar
• Bansal N, Gupta A, N SANKHWARS. Proteometabolomics of bladder cancer: current and future prospects [J]. Cancer Biomark. 2015;15(4):339–348.
   PubMed Web of Science ®Google Scholar
• C MILLSC, A KOLBE, B SAMPSONV. Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy [J]. Cancer Res. 2018;78(2):320–325.
   PubMed Web of Science ®Google Scholar